recanalization, 24-hour follow up imaging, and mRS at 90 days.

Result In these 29 patients, they were 14 were males, 68 years old (42–81 years old). The initial NIHSS at emergency department was 27 (standard deviation (SD)= 7.3); 8 of them received IV-tPA, the average time from onset to needle was 417 minutes (SD = 38.9); 93.1% (27/29) using aspiration as first method of recanalization; TICI =3 or 2b in 86.2% (25/29); 41.4% (12/29) associated with basilar artery stenosis; on the 24-hour follow up imaging, parenchymal hemorrhage was found in 3 and hemorrhagic transformation in 3; the mRS (0–2) at 90 days was 55.1% (16/29), and the mortality rate was 10.3% (3/29).

Conclusion Acute basilar artery occlusion is a complex and severe disease, endovascular thrombectomy can have a high rate of recanalization but the clinical outcome on 90 days still worse than the one in anterior circulation. The treatment will become more challenge in patient associated with underlying intracranial atherosclerotic stenosis.

Disclosures H. Liu: 3; C; Stryker, GE. C. Lee: None. Y. Lin: None. C. Wan: None.

8 INTRA-ARTERIAL THROMBOLYSIS AS RESCUE THERAPY IN MCA OCCLUSIONS: SUBANALYSIS FROM THE STRATIS REGISTRY

¹A Castonguay*, ¹S Zaidi, ¹M Jumaa, ²O Zaidat, ³D Liebeskind, ¹H Salahuddin, ⁴N Mueller-Kronast. ¹University of Toledo, Toledo, OH; ²Mercy St. Vincent, Toledo, OH; ³UCLA, Los Angeles, CA; ⁴Delray Medical Center, Delray Beach, FL

10.1136/neurintsurg-2019-SNIS.231

Background and purpose Recent data suggests that intra-arterial (IA) thrombolytics may be a safe rescue therapy (RT) for acute ischemic stroke (AIS) patients after failed mechanical thrombectomy (MT); however, its safety and efficacy in MCA occlusions remains unclear. Here, we investigate the use of IA tissue plasminogen activator (IA-rtPA) as RT in MCA occlusions in the Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke (STRATIS) Registry.

Methods The STRATIS Registry was a prospective, multicenter, non-randomized, observational study of AIS LVO patients treated with the Solitaire stent-retriever as the first choice therapy within 8 hours from symptoms onset. Clinical and angiographic outcomes were compared in patients with MCA occlusions treated with and without IA-rtPA.

Results A total of 680/938 (72.5%) patients with IA-tPA use harbored MCA occlusions, of which 585 (86.0%) and 95 (14.0%) were in the no IA-rtPA and IA-rtPA groups, respectively. Baseline demographics were well-balanced between the cohorts. The majority of MCA occlusions were located in the M1 segment, with 76.1% in the no IA-rtPA group and 74.7% in the IA-rtPA group ($p=0.80$). IV-rtPA was administered in 64.4% and 71.6% of the no IA-rtPA and IA-rtPA patients ($p=0.20$). Median IA-rtPA dose was 4mg (IQR 2–10) in the IA-rtPA cohort. Onset to puncture time was less than 6 hours in 88.6% (597/674) of patients. Mean onset to arterial puncture time was shorter in the IA-rtPA group (196.7 ± 109.9 versus 228.2 ± 97.9 minutes, $p=0.004$); however, mean puncture to procedure end time was longer in the IA-rtPA group than the no IA-rtPA group (74.5 ± 41.5 versus 59.5 ± 33.6 minutes). Mean number of passes (2.0 ± 1.2 versus 1.6 ± 1.0 , $p=0.005$) and rate of distal embolization

(53.4% versus 72.1%, $p=0.001$) were significantly higher in the IA-rtPA group. The rate of substantial reperfusion ($mTICI \geq 2b$) was similar in the cohorts (89.9% versus 86.0%, $p=0.28$). Rates of symptomatic intracranial hemorrhage (sICH) (1.7% versus 2.2%, $p=0.68$), good functional outcome ($mRS \leq 2$, 60.5% versus 58.0%, $p=0.85$), and mortality (13.9% versus 13.6%, $p=0.96$) at 90days did not differ between the two groups.

Conclusion Use of IA-rtPA as rescue therapy after failed mechanical thrombectomy in MCA occlusions was not associated with an increased risk of sICH or mortality in the STRATIS Registry. More studies are needed to understand the safety and efficacy of IA thrombolysis as rescue therapy in this patient population.

Disclosures A. Castonguay: None. S. Zaidi: None. M. Jumaa: None. O. Zaidat: None. D. Liebeskind: None. H. Salahuddin: None. N. Mueller-Kronast: None.

9 FACTORS ASSOCIATED WITH THE DECISION-MAKING ON ENDOVASCULAR THROMBECTOMY FOR THE MANAGEMENT OF ACUTE ISCHEMIC STROKE

¹M Goyal*, ²B Menon, ³N Kashani, ³A Wilson, ⁴S Yoshimura, ⁵B Campbell, ⁶B Baxter, ⁷A Rabinstein, ⁸F Turjman, ⁹U Fischer, ¹⁰J Ospel, ¹¹W Kunz, ¹²P Mitchell, ¹³P Sylia, ¹⁴M Cherian, ¹⁵B Kim, ¹⁶J Heo, ¹⁷A Podlasek, ³M Almekhlafi, ³M Foss, ¹⁸A Demchuk, ¹⁸M Hill, ¹⁹G Saposnik. ¹Radiology, Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; ²Clinical Neurosciences, University of Calgary, Calgary, AB, Canada; ³Radiology, University of Calgary, Calgary, AB, Canada; ⁴Neurosurgery, Hyogo College of Medicine, Hyogo, Japan; ⁵Neurology, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia; ⁶Radiology, Erlanger Hospital Chattanooga, Chattanooga, TN; ⁷Radiology, Mayo Clinic Rochester, Rochester, MN; ⁸Radiology, Centre Hospitalier Universitaire de Lyon, Lyon, France; ⁹Radiology, University Hospital Bern (Inselspital), Bern, Switzerland; ¹⁰Radiology, University Hospital Basel, Basel, Switzerland; ¹¹Radiology, University Hospital Munich, Munich, Germany; ¹²Radiology, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia; ¹³Radiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, India; ¹⁴Radiology, Kovai Medical center, Tamil Nadu, India; ¹⁵Radiology, St. Mary's Hospital Seoul, Seoul, Korea, Republic of; ¹⁶Neurology, Yonsei University, Seoul, Seoul, Korea, Republic of; ¹⁷Radiology, Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, UK; ¹⁸Neurology, University of Calgary, Calgary, AB, Canada; ¹⁹Neurology, St. Michael's hospital, Toronto, ON, Canada

10.1136/neurintsurg-2019-SNIS.232

Background and Purpose Little is known about the real-life factors that clinicians use in selection of patients that would receive endovascular treatment (EVT) in the real world. We sought to determine patient, practitioner, and health system factors associated with therapeutic decisions around endovascular treatment.

Methods We conducted a multinational cross-sectional web-based study comprising of 607 clinicians and interventionalists from 38 countries who are directly involved acute stroke care. Participants were randomly allocated to 10 from a pool of 22 acute stroke case scenarios and stated how they would treat the patient A) under current local resources, and B) under assumed ideal conditions (i.e. without monetary or infrastructural constraints). Descriptive statistics and logistic regression was performed to determine multilevel factors associated with EVT, adherence to current EVT guidelines, and practice gaps between current local resources and assumed ideal conditions.

Results Of the 1330 invited participants, 607 (45.6%) participants completed the study (53.7% neurologists, 28.5% neuro-interventional radiologists, 17.8% other clinicians). NIHSS (34.9%), level of evidence (30.2%), ASPECTS or ischemic core volume (22.4%), patient's age (21.6%), and clinicians'

Abstract 9 Figure 1

experience in EVT use (19.3%) are the most important factors for EVT decision. Of all responses that met Class IA evidence for EVT, 86.8% were in favor of EVT. In case scenarios Class IIB evidence, 66.3% of responses favored EVT. Comparison between current and ideal practice settings revealed an overall practice gap of 4% (Class 1A evidence scenarios) and 3% (Class 2B evidence scenarios). EVT decision rates differed significantly between regions and specialties under current local resources ($p < .001$ respectively), but not under assumed ideal conditions ($p = .563$ and $.397$).

Conclusions In this large multinational survey, stroke severity, guideline-based level of evidence, baseline brain imaging, patients' age and physicians' experience were the most relevant factors for EVT decision-making. The high agreement between responses and Class I guideline recommendations and high EVT use even when guidelines were not available reflect the real-world acceptance of EVT as standard of care in patients with disabling acute ischemic stroke. The overall practice gap and the significant differences in EVT decision rates

under current local resources suggest that physicians of different specialties and practicing in different geographic regions succumb to variable external restraints.

Disclosures M. Goyal: 1; C; This study was funded through an unrestricted Research Grant to the University of Calgary by Stryker Inc. 2; C; Medtronic, Stryker, Microvention, GE Healthcare, Mentice. B. Menon: None. N. Kashani: None. A. Wilson: None. S. Yoshimura: None. B. Campbell: None. B. Baxter: 2; C; Penumbra, Medtronic, Stryker, 880 Medical, Metactive. 4; C; Penumbra, viz.ai. 5; C; ownership interests on Route 92 and Marblehead. A. Rabinstein: None. F. Turjman: 2; C; consultant for Balt and Stryker. U. Fischer: 2; C; Medtronic, Stryker, CSL Behring. 6; C; Co-PI Swift direct trial (Medtronic). J. Ospel: None. W. Kunz: None. P. Mitchell: None. P. Sylaja: None. M. Cherian: None. B. Kim: None. J. Heo: None. A. Podlasek: None. M. Almekhlafi: None. M. Foss: None. A. Demchuk: None. M. Hill: None. G. Saposnik: 6; C; Gustavo Saposnik is supported by the Heart and Stroke Foundation of Canada Career Award.